All Posts

New Patient Surveys to Assist in Designing the Next Phase of COMPPARE

In early June, COMPPARE Coordinators administered over 500 surveys to participants. The purpose of the surveys is to guide the design of the next grant proposal to secure funding to follow COMPPARE patients another five years.  More participants will receive surveys in the coming weeks. New information has emerged that…

What’s Next for COMPPARE?

Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up Questionnaires.

COMPPARE Completes Patient Enrollment

After four years and 2,524 enrolled patients, the COMPPARE team officially closed patient accrual to the study on October 31, 2022 at 11:59 p.m. EST. “This is an important milestone and we appreciate the patients who have agreed to participate and all of the hard work on the part of…

COMPPARE Enrolls 1,000th Photon Patient

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…

September is Prostate Cancer Awareness Month

If you are a man between the ages of 55 and 69, September is a good time to schedule a prostate screening, one that includes both a PSA blood test and prostate examination. Consider the numbers: Prostate cancer is the most common genitourinary cancer treated by a urologist and the…

COMPPARE Enrolls 1,500th Proton Patient, Reaches Cohort Goal

The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…

COMPPARE Achieves 75% Enrollment Milestone

The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…

From Principles to Practice: Building Partnerships for Trust and Equity in Health Research with COMPPARE

On November 17, Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, participated in a special panel discussion entitled “From Principles to Practice: Building Partnerships for Trust and Equity in Health Research” during the 7th annual meeting of the Patient-Centered Outcomes Research Institute (PCORI). “This year’s…